Molecular Biomarker Analyses Using Circulating Tumor Cells
Elizabeth A. Punnoose, Siminder Kaur Atwal, Jill M. Spoerke et al. · PLoS ONE · 2010
BACKGROUND: Evaluation of cancer biomarkers from blood could significantly enable biomarker assessment by providing a relatively non-invasive source of representative tumor material. Circulating Tumor Cells (CTCs) isolated from blood of metastatic cancer patients hold significant promise in this regard. METHODOLOGY/PRINCIPAL FINDINGS: Using spiked tumor-cells we evaluated CTC capture on different CTC technology platforms, including CellSearch and two biochip platforms, and used the isolated CTCs to develop and optimize assays for molecular characterization of CTCs. We report similar performance for the various platforms tested in capturing CTCs, and find that capture efficiency is dependent on the level of EpCAM expression. We demonstrate that captured CTCs are amenable to biomarker analyses such as HER2 status, qRT-PCR for breast cancer subtype markers, KRAS mutation detection, and EGFR staining by immunofluorescence (IF). We quantify cell surface expression of EGFR in metastatic lung cancer patient samples. In addition, we determined HER2 status by IF and FISH in CTCs from metastatic breast cancer patients. In the majority of patients (89%) we found concordance with HER2 status from patient tumor tissue, though in a subset of patients (11%), HER2 status in CTCs differed from that observed in the primary tumor. Surprisingly, we found CTC counts to be higher in ER+ patients in comparison to HER2+ and triple negative patients, which could be explained by low EpCAM expression and a more mesenchymal phenotype of tumors belonging to the basal-like molecular subtype of breast cancer. CONCLUSIONS/SIGNIFICANCE: Our data suggests that molecular characterization from captured CTCs is possible and can potentially provide real-time information on biomarker status. In this regard, CTCs hold significant promise as a source of tumor material to facilitate clinical biomarker evaluation. However, limitations exist from a purely EpCAM based capture system and addition of antibodies to mesenchymal markers could further improve CTC capture efficiency to enable routine biomarker analysis from CTCs.
Cited by 294 works. doi:10.1371/journal.pone.0012517 Open-access PDF
Authors
- Elizabeth A. Punnoose
- Siminder Kaur Atwal
- Jill M. Spoerke
- Heidi M. Savage
- Ajay Pandita
- Ru‐Fang Yeh
- Andrea Pirzkall
- Bernard M. Fine
- Lukas C. Amler
- Daniel S. Chen
- Mark R. Lackner
References
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
- Isolation of rare circulating tumour cells in cancer patients by microchip technology
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
- Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases
- Detection of Mutations in EGFR in Circulating Lung-Cancer Cells